Dolby Laboratories, Inc. (DLB) financials: revenue, earnings and cash flow
Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026
Summary
Dolby Laboratories’s revenue went from $1.0B in fiscal 2016 to $1.3B in fiscal 2025, growth of about 3.1% a year.
Net income in fiscal 2025 was $255M, a net margin of 18.9%; the best year in this period was 2021 with $310M.
Over the twelve months to June 26, 2026, revenue was $1.4B and net income $226M.
Free cash flow was $436M in fiscal 2025 and positive in 10 of the 10 years shown.
The diluted share count fell 67% over the period (buybacks).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.4B | $1.3B | $1.3B | $1.3B | $1.3B | $1.3B | $1.2B | $1.2B | $1.1B | $1.1B | $1.0B |
| Gross profit | $1.2B | $1.2B | $1.1B | $1.1B | $1.1B | $1.2B | $1.0B | $1.1B | $927M | $962M | $917M |
| Operating income | $239M | $265M | $258M | $216M | $207M | $344M | $219M | $257M | $184M | $247M | $232M |
| Net income | $226M | $255M | $262M | $201M | $184M | $310M | $231M | $255M | $42M | $206M | $186M |
| EPS (diluted) | $2.35 | $2.62 | $2.69 | $2.05 | $1.81 | $2.97 | $2.25 | $2.44 | $0.39 | $2.00 | $0.62 |
| R&D | $266M | $262M | $264M | $272M | $261M | $254M | $239M | $238M | $237M | $233M | $220M |
| Revenue growth | — | +5.9% | −2.0% | +3.7% | −2.1% | +10.3% | −6.4% | +17.7% | −2.4% | +5.3% | +5.7% |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $438M | $472M | $327M | $367M | $319M | $448M | $344M | $328M | $352M | $378M | $360M |
| Capital spending | -$45M | -$36M | -$30M | -$30M | -$48M | -$54M | -$66M | -$96M | -$73M | -$100M | -$101M |
| Free cash flow | $393M | $436M | $297M | $337M | $271M | $393M | $278M | $231M | $279M | $278M | $259M |
| Dividends paid | $134M | $127M | $115M | $103M | $100M | $89M | $89M | $77M | $66M | $57M | $48M |
| Buybacks | $235M | $125M | $160M | $149M | $530M | $246M | $174M | $341M | $150M | $100M | $101M |
| Stock-based pay | $130M | $129M | $120M | $118M | $115M | $100M | $87M | $77M | $71M | $65M | $67M |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $703M | $482M | $885M | $809M | $1.3B | $1.1B | $916M | $1.1B | $882M | $641M |
| Debt | — | $39M | $47M | $51M | $51M | $72M | $81M | $65M | — | — | — |
| Equity | — | $2.6B | $2.5B | $2.4B | $2.2B | $2.6B | $2.4B | $2.3B | $2.4B | $2.1B | $2.0B |
| Total assets | — | $3.2B | $3.1B | $3.0B | $2.7B | $3.1B | $2.9B | $2.8B | $2.9B | $2.5B | $2.3B |
| Shares (diluted) | 95M | 97M | 97M | 98M | 102M | 105M | 103M | 105M | 107M | 103M | 299M |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 87.6% | 88.1% | 89.0% | 88.3% | 88.7% | 89.8% | 87.4% | 87.0% | 87.9% | 89.0% | 89.4% |
| Operating margin | 17.7% | 19.6% | 20.3% | 16.6% | 16.5% | 26.9% | 18.8% | 20.7% | 17.4% | 22.9% | 22.6% |
| Net margin | 16.7% | 18.9% | 20.6% | 15.4% | 14.7% | 24.2% | 19.9% | 20.5% | 4.0% | 19.1% | 18.1% |
| FCF margin | 29.0% | 32.3% | 23.3% | 25.9% | 21.6% | 30.7% | 23.9% | 18.6% | 26.5% | 25.8% | 25.3% |
| ROIC | — | 8.4% | 8.7% | 7.2% | 7.7% | 11.6% | 8.4% | 9.8% | 6.1% | 9.4% | 9.3% |
| ROE | — | 9.7% | 10.6% | 8.5% | 8.2% | 11.9% | 9.5% | 11.1% | 1.8% | 9.7% | 9.4% |
Frequently asked questions
What is Dolby Laboratories’s annual revenue?
$1.3B in fiscal 2025 and $1.4B over the twelve months to June 26, 2026.
How much profit does Dolby Laboratories make?
Net income was $255M in fiscal 2025 (net margin 18.9%).
Is Dolby Laboratories’s revenue growing?
Yes: revenue rose 5.9% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.